MedTrace Logo

Lung Function Changes of Induced Asthma Children Treated With Inhaled MgSO4

NCT01856959 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2013-05-20

No results posted yet for this study

Summary

As a non-selective bronchodilator, magnesium sulfate (MgSO4) is effective when administered intravenously in the treatment of the patients with acute severe asthma not responding to conventional therapy (oxygen, nebulized salbutamol, and corticosteroids), which can resulted in earlier improvement in clinical signs and symptoms of asthma and PEF. However, the use of intravenous MgSO4 administered is not common in clinical practice, because it's prone to have adverse effects and side effects such as nausea, vomiting, facial flushing, hypotension, decreased tendon reflexes and so on with this treatment. The aerosolised route offers the advantage of lower dosage, a shorter time of drug being delivered to the airway smooth muscle and lower incidence of side effects when compared to the intravenous route. At present, there are only a few studies about the effects of nebulized MgSO4 in the treatment of acute asthma in children, and the conclusions are controversial.

Conditions

Interventions

DRUG

Magnesium Sulfate

2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg

DRUG

magnesium sulfate & albuterol

0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg

DRUG

Albuterol

0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg

Sponsors & Collaborators

  • Chongqing Medical University

    lead OTHER

Principal Investigators

  • Jihong Dai, M.D. · Chongqing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-03-31
Completion
2013-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01856959 on ClinicalTrials.gov